Deals In Depth: June/July 2013
In a regional deal, AstraZeneca licensed rights to FibroGen’s renal candidate in an alliance worth $815 million; Elan finally agreed to an $8.3 billion takeover by Perrigo; biopharma financing totaled $7.1 billion and $2 billion in June and July, respectively, while device fundraising reached $325 million and $316 million in the same months.
You may also be interested in...
Investing in oncology has diminished as more focus goes to clinical-stage firms, while investment in preclinical companies in areas like neurology has been heating up.
Based on advice from the FDA, Cardiff is testing its PLK1 inhibitor onvansertib in first-line metastatic colorectal cancer; data from a discontinued second-line trial may support the hypothesis.
ViVE 2024: Start-Ups Using AI To Screen Children’s Mental Health, Prevent Post-Partum Depression, Health Equity, More
Medtech Insight features seven start-ups that pitched their innovative projects at ViVE’s inaugural Start-up Competition in Los Angeles.